Partnerships
Join us to build innovative solutions and make medicine accessible
We collaborate with healthcare partners, including pharmaceutical companies and hospitals, to impact global patient health. Quality and compliance are prioritized, keeping the patient central.
Info-Jini - Knowledge support for doctors
Info-jini is a unique service that provides valuable scientific information inputs to doctors. To help them keep pace with medical advancements, Info-jini gives doctors access to latest, evidence-based medical data required to make informed clinical decisions.
PromOTE India - Cancer diagnosis initiative for Primary Health Physicians
Conducted in association with the Indian Co-operative Oncology Network (ICON), PromOTE India (Promotion of Oncology Training and Education in India) is an initiative aimed at early detection and diagnosis of cancer. Primary health physicians are educated about early stage diagnosis and detection by eminent oncologists.
E-Hypertension Academy - Hypertension management program for CPs
A collaboration with the Association of Physicians of India (API), the e-Hypertension Academy initiative aims to upgrade the knowledge and expertise of practicing physicians in the field of hypertension management. The modules covered in the certificate course are also webcasted in multiple locations across India.
Articles & Case Studies
Sustainablity
Our approach
Sustainability in one of our core values, and rooted in our purpose of providing access to affordable and innovative medicines. We believe that our long-term success is closely integrated with our ability to operate in a responsible, ethical, transparent manner, while supporting the communities we live and operate in. We are committed to advancing sustainability in the way we do business, integrating it in our decisions and strategy, and focusing on long term sustainable growth.
Our ESG commitments are centred around creating positive social impact for our patients and employees, reducing our environmental footprint, and ensuring responsible business practices to build trust with our diverse stakeholders. Strong governance mechanisms and policy frameworks help us operationalise and deliver on our commitments, and our goal of reaching 1.5 billion patients by 2030 guides us as we work every day to enhance access, affordability and innovation through our medicines, reduce the global disease burden, and improve patient health outcomes.
Our goals pave the way for
a sustainable future
Making our products accessible and affordable for patients
Enhancing trust with our stakeholders
Contributing to a fairer and more socially inclusive world
Being committed to environmental stewardship
Impact we had on the environment
Quick Access
Our Credentials
20 Years of leading the industry in Sustainability
In 2004, we took a significant step by publishing our inaugural sustainability report. This document not only showcased environmental impact up to that point but also outlined ambitious goals for the future, demonstrating our commitment to sustainability and responsible practices.
Description for 2006.
Description for 2009.
Description for 2009.
Description for 2009.
Description for 2009.
Dr. Anji Reddy’s Spirit Of Giving
Actions speak louder than words and nothing exemplifies this better than what we do to build better communities. At the commemoration of our founder’s passing every year, we launch Dr. Anji Reddy’s Spirit of Giving programme, where our employees across the world volunteer and contribute their time and effort to make a difference to society.\n\nFostering scientific temper among schoolchildren, spending time with senior citizens, bringing cheer to orphans, spreading awareness about traffic rules, working to restore a cyclone-ravaged zoo — the causes are many and diverse, but the commitment is the same\n\nThe Dr. Anji Reddy’s Spirit of Giving programme truly demonstrates the culture of giving Dr. Anji Reddy imbued in our company ethos
Our Buisnesses
We believe in pursuing purposeful strategy
Our business strategy rests on three core pillars of leadership in chosen spaces, operational excellence and continuous improvement, along with patient-centric product innovation underpinned by sustainability.
Making essential medicines accessible and affordable across the world
Blending affordability with familiarity through patient-trusted brands.
We aim to provide affordable medicines to improve patient access to therapies.
For APIs, we are a partner of choice for international pharmaceutical companies
We aim to provide affordable medicines to improve patient access to therapies.
We aim to provide affordable medicines to improve patient access to therapies.
A foundation you can rely on
Explore our API offerings, and partner with us to bring quality and affordable medicines to patients everywhere.
Empowering patients through dedicated programs
Sparsh aids economically challenged patients in chemotherapy, helping over 6,000 underprivileged cancer patients facing high treatment costs.
Committed to Help, Educate and Encourage Renal patients is a support program to improve adherence to therapy for Chronic Kidney Disease (CKD) patients.
Mitr – a toll-free helpline is a confidential psychological / emotional support service program for cancer patients.
Advancing healthcare through professional programs
A hypertension management program for HCPs with guidelines for diagnosis, treatment, patient education, and monitoring techniques.
An initiative to enhance Primary Health Physicians' cancer diagnosis. It provides training, resources, and support for early detection and better outcomes.
An initiative to enhance Primary Health Physicians' cancer diagnosis. It provides training, resources, and support for early detection and better outcomes.
Info-jini is a unique service providing scientific information to doctors. It gives access to evidence-based medical data for informed clinical decisions.
Keeping sustainability in mind
in everything we do
Learn more about what we do
A platform that lets pharmacies order medicines online with a few clicks, streamlining procurement and saving time.
Learn more about our OTC products and get guidance on drug usage, adverse effects and more
Newsroom
We’ve created a guideline for media and press on the representation of Dr. Reddy’s brands in any visual media.
Reach out to our
Media Relations Team
Test Section
Section Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. \n\nLorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Section Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. \n\nLorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Learn more about our Biologics business
Branded Generics
Our Offerings
We use Quality by Design techniques to produce complex molecules enabling customers to create successful formulations. Our 8 global manufacturing units run in accordance with Current Good Manufacturing Practices (cGMP) and have been successfully audited by international regulatory bodies such as the US Food and Drug Association (FDA).\n\nOur supply chain is resilient, supported by strategic sourcing partnerships. We provide excellent customer service through a dedicated team of quality, regulatory, and commercial experts. As a member of the Pharmaceutical Supply Chain Initiative, we are committed to sustainable supply chain practices based on the principles of ethics, human rights and labour, health and safety, environment, and management systems. We strive to bring complex products and enable launches ahead of others at competitive prices. We offer niche capabilities and technology platforms at competitive cost structures to innovator and biotechnology companies.
Growing base
We plan to grow the API business by launching new products through backward integration into core molecules, and by boosting our business in key geographies. In FY2024, we filed 133 drug master files (DMFs) globally, of which 11 were in the U.S. Cumulatively, our total active DMFs filed worldwide as of March 31, 2024 were 1,861, including 251 active DMFs filed in the U.S. We have an equally strong pipeline of products.\n\nWe have also moved up the chain from providing simple APIs to supplying value-added APIs to our institutional customers in over 25 countries, and intend to expand this product basket to over 60 countries (June ’23).\n\nWe utilize flow chemistry for hazardous and cryogenic reactions. The driver to adopt this is a move towards sustainable manufacturing with improved green metrics, lower operating costs, and minimal manual operations. We are also in the process of commissioning a modular plant for an intermediate to API process encompassing multiple reactions and unit operations.\n\nFor several international pharmaceutical companies, we are a partner of choice for APIs and will continue to maintain our leadership through new product offerings, cost competencies, and high service standards.
Learn more about our API business